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Between 1981 and 1988, 107 percutaneous transluminal coronary angioplasty (PTCA) procedures, including repeat
PTCA, were performed in 84 patients with previous coronary artery bypass grafting (CABG). Fifty-nine patients under-
went a first angioplasty of the vein graft alone, and 25 underwent a first PTCA of the graft and one or more native vessels.
Seventeen patients underwent two procedures, four patients three procedures and one patient four procedures. In 84 first
angioplasties, 133 lesions were attempted; 40 lesions in native vessels and 93 graft lesions (28 ostial stenoses, 33 shaft
stenoses, and 32 stenoses at the distal anastomosis).
Three patients died during their hospital stay. Two patients underwent emergency CABG. Seven patients sustained an
acute myocardial infarction (AMI), among whom five underwent a PTCA of an occluded vessel. The clinical primary
success rate per patient was 82%. After five years, 70% of patients were alive. At a median follow-up of 21 years, 41% of
patients were alive and event-free (no AMI, no repeat CABG, no repeat PTCA). Symptomatic improvement was main-
tained in 36% of patients. Angioplasty of grafts may be an alternative to re-operation in selected patients with previous
bypass surgery.
Introduction
Coronary artery bypass grafting (CABG) has developed
into a safe and effective procedure for relieving refractory
angina, and improves prognosis in selected patients with
left main or multivessel coronary artery disease. However,
recurrent symptoms of myocardial ischaemia often
develop after bypass surgery, requiring either re-
institution of medical therapy or repeat bypass surgery.
Repeat direct myocardial revascularization is techni-
cally more difficult and is generally associated with a higher
morbidity and mortality than the initial surgery1'"6'.
Although percutaneous transluminal coronary angio-
plasty (PTCA) is an attractive alternative to re-operation
in patients with prior bypass surgery, the long-term
results of this procedure have only been published over
the last two or three years'78'. This report describes our
experience with the use of angioplasty in the treatment of
partially or totally occluded saphenous vein bypass grafts.
Methods
STUDY PATIENTS
Between February 1981 and October 1988, 2620
consecutive PTCA procedures were performed at the
Thoraxcenter in Rotterdam. All 84 consecutive patients
with previous bypass surgery who underwent a first
PTCA of the saphenous vein bypass graft alone (59
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patients), or a first PTCA of the graft and one or more
native vessels (25 patients), were retrospectively reviewed
and provide the basis for this study. In these 84 patients
107 (41%) bypass graft angioplasty procedures, includ-
ing repeat angioplasties, were performed. Fifteen (18%)
patients underwent a dilatation of an occluded saphenous
vein graft.
Fifty-six patients (67%) received an aortocoronary
circular sequential saphenous vein graft. A proximal
occlusion was located between the connection of the aorta
and the first anastomosis, a mid-occlusion after the first
anastomosis and before the most distal anastomosis, and
a distal occlusion in the distal part of the graft. Seven of
the 56 patients also had a single graft. Single grafts alone
were placed in 26 patients. Two patients had received a
snakegraft. The mean interval between coronary bypass
surgery and coronary angioplasty was 4-7 years (range 1
month to 13-5 years). Eight patients (10%) had coronary
angioplasty within 6 months and 18 (21%) within one
year of coronary bypass surgery. Thirty-nine patients
(46%) had a PTCA more than 5 years after CABG (Fig.
1). Two patients had had two previous bypass procedures.
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Figure 1 Time interval between PTCA and previous surgery.
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In 84 primary angioplasties, 133 lesions were
attempted. There were 93 lesions in the saphenous vein
bypass grafts, and 40 lesions in native vessels. The 93
bypass graft stenoses consisted of 28 (30%) proximal
stenoses, 33 (36%) stenoses in the shaft of the graft, and 32
(34%) at the distal end to side anastomosis. Twenty-five
patients underwent a PTCA of the graft and one or more
native vesseis; the number of attempted native vessel
stenoses ranged from one to three per patient (mean: 1 -9).
Angiographic success was defined as a reduction in the
severity of all attempted lesions to less than 50% luminal
diameter narrowing. Clinical success was defined when
angiographic success was achieved with the abolition of
acute ischaemic symptoms and without progression to
myocardial infarction, emergency surgery or death.
All patients had stable or unstable angina pectoris
despite intensive pharmacological therapy, and were con-
sidered to be appropriate candidates for repeat bypass
surgery. Sixty-five (77%) of the patients were men. The
mean age was 60 years, ranging from 39 to 79 years.
Before angioplasty, the New York Heart Association
classification was class 2 in 14 (17%), class 3 in 31 (37%),
and class 4 in 39 (46%). Twenty patients (24%) had
hypertension (blood pressure higher than 140/90 mmHg),
10 patients (12%) had diabetes mellitus requiring medi-
cation, 18 (21%) had hypercholesterolaemia (more than
240mg.dr'), and 54 (64%) had a history of previous
acute myocardial infarction (AMI). Five patients (6%)
had single-vessel disease, 21 (25%) two-vessel and 58
(69%) triple-vessel disease.
The left ventricular ejection fraction was calculated
from contrast ventriculography, as previously described'91.
The mean ejection fraction was 0-55 ±013. Eight (10%)
patients had an ejection fraction of less than 0-35.
CORONARY ANGIOPLASTY
Management decisions on the individual patients were
made after review of the coronary arteriograms and dis-
cussion with the cardiothoracic surgeons. Patients were
referred for angioplasty if the lesions considered respon-
sible for significant myocardial ischaemia documented by
objective noninvasive studies (exercise stress testing or
myocardial scintigraphy (when not clinically contra-
indicated) and by coronary cinearteriography, were
thought both by the cardiologist and the cardiac surgeon,
to be technically suitable for PTCA.
The patient's coronary anatomy was the primary deter-
minant of whether or not angioplasty would be
attempted. However, some patients underwent a PTCA
because they were not considered good candidates for
bypass surgery. This surgical risk assessment was deter-
mined by the presence of multiple prior bypass operations
with or without postoperative complications, concomi-
tant severe medical conditions (for example severe
diabetes mellitus with marked end-organ damage, renal
failure) or severe left ventricular dysfunction (left
ventricular ejection fraction ^35%).
The procedure used in our laboratory has been pre-
viously described'10"12'. Before the procedure, 250 mg of
acetylsalicylic acid and 10000U of heparine were
administered intravenously. All procedures were per-
formed with surgical stand-by. After the procedure, all
patients were followed up for 24 h in the medium care
unit, where the ECG and cardiac enzyme levels were
monitored. A peri-interventional myocardial infarction
was diagnosed if either new pathologic Q waves devel-
oped or a cardiac enzyme elevation (>2 times normal
value) was documented. Following successful angio-
plasty, patients were continued on nifedipine, 40 to 60 mg
day"1, and aspirin, 500 mg day"1, for a period of 6
months after PTCA.
TECHNICAL ASPECTS
The method of angioplasty changed during the study
period: prior to February 1983 a non-steerable catheter
system was used; after then, the long guide-wire technique
or a monorail system was used. Angioplasty of the lesion
considered to be the most important (according to severity
and morphology of the lesion, size of vessel or graft, wall
motion of area at risk and localization of ischaemic
electrocardiographic changes at rest) was attempted first.
All angioplasty procedures were performed by utilizing
the femoral (66 patients) or brachial (15 patients) tech-
niques, or both (three patients). Guiding catheter selec-
tion was determined by the configuration and orientation
of the saphenous vein graft and the diameter of the
ascending aorta. The mean maximal inflation pressure
was 11-0 + 2-3 atmospheres (range 5 to 18) with a mean
maximal inflation time of 189 ± 147 seconds (range 10 to
740).
FOLLOW-UP
Procedural details, including complications, were
recorded at the time of the PTCA in our database.
Primary end-points considered at follow-up were death,
non-fatal myocardial infarction, recurrent angina pectoris
necessitating repeat bypass surgery or repeat angioplasty,
and symptomatic improvement. Follow-up information
was available in 100% of patients. It was first established
for all patients whether they were still alive, by means of a
letter to the civil registry. If they were alive, follow-up data
were obtained by questionnaires and by telephone
(97-6%), or by interview during out-patient visits (2-4%).
STATISTICS
All data are presented as the mean +1 standard
deviation. Life table analysis was performed according to
the Kaplan-Meier method. The generalized Willcoxon or
Breslow test was utilized to detect differences between
the sub-groups. A P value of <005 was considered
statistically significant.
Results
INITIAL RESULTS
The angiographic primary success rate per lesion was
88% for bypass graft stenoses, and 93% for native vessel
stenoses. The angiographic primary success rate was 86%
for proximal lesions, 97% for shaft lesions, and 81% for
distal lesions (Table 1). The clinical primary success rate
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Table 1 Primary angiographic success at first PTCA (per lesion)
Lesion site Lesions(n)
Successful
(n)
SVG proximal
middle
distal
Native artery
Total
28
33
32
40
133
24/28
32/33
26/32
37/40
119/133
86
97
81
93
89
SVG: saphenous vein graft.
1st event
Death 8 -
-Cllnlcol success-
69
-AMI 7
-CABG 15
-rePTCA 6
Functional| Improvement 25
-Event-free survival
33
No functional
"improvement 8
I Medical treatment 2
Death I
I Elective CABG I
I No complications 4
-Clinical failure
15
-Complications II
-AMI 7
-Death I
-Acute CABG 2 —
-Elective CABG I -
-AMI I
— Death I
Figure 2 Results of angioplasty of bypass grafts: procedural com-
plications at first angioplasty and long-term follow-up after success-
ful angioplasty. AMI: acute myocardial infarction; CABG: coronary
artery bypass grafting; rePTCA: repeat percutaneous transluminal
coronary angioplasty.
per patient was 82%; 69 of the 84 primary procedures
were successful and without complications. The clinical
primary success rate was 72% for patients who underwent
a PTCA of the graft and one or more native vessels and
86% for patients who underwent a PTCA of the bypass
graft alone. After February 1983, when the PTCA pro-
cedures were carried out with the long guide-wire tech-
nique or a monorail system, a higher clinical primary
success rate was found (85% versus 67%). However, only
14% of the procedures were performed before February
1983.
Thirteen complications occurred in 11 patients (Fig. 2).
There was one procedure-related death, and two patients
died during their hospital stay. Of these two patients one
died of an acute myocardial infarction 3 days after the
PTCA attempt had failed, and the other died of renal
failure 10 days after an elective repeat CABG. Two
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Figure 3 The cumulative probability of survival in 84 patients with
prior bypass surgery after attempted PTCA of the vein graft alone, or
of the graft and one or more native vessels, was 70% at 5 years. The
left ventricular ejection fraction was a variable adversely affecting
long-term survival (P <005). The numbers in the lower half indicate
the number of patients alive at the end of each year. EF: ejection
fraction.
patients required emergency surgery; one of them
sustained an acute myocardial infarction.
Fifteen of the 84 patients underwent angioplasty in the
setting of a recanalization of a chronic occluded bypass
graft. Nine of the 15 procedures were angiographically
successful: the angiographic primary success rate was
60%. Five of the 15 patients sustained a procedure-related
myocardial infarction, which was caused by a distal
embolization of bypass graft atheroma. Four of the five
patients sustained a myocardial infarction shortly after an
angiographically successful PTCA (creatine kinase (CK):
6 8 4 I i r \ 280IIT1, 800IU"1 and 2900IU"1), and
PTCA was not successful in one patient (CK: 1200 IU"1).
Of the patients who underwent angioplasty of a non-
occluded graft, two patients sustained a myocardial
infarction; one patient after an angiographically success-
ful PTCA (CK unknown) and one patient after a failed
PTCA attempt (CK 199 IU"1). In both patients the cause
of the infarction was an acute occlusion after a dissection
in the dilated segment.
The PTCA procedure failed without complications in
two cases: in one patient there was failure to cross the
stenosis, and in one case, although inflation of the balloon
to the maximal pressure limits was achieved, there was
insignificant change in the stenosis after angioplasty.
FOLLOW-UP
The median follow-up period was 21+0-4 years.
Thirteen patients died; eight patients died of cardiac
events, three patients died of non-cardiac events, and the
cause of death was unknown in two patients. Life table
analysis (Fig. 3) showed a cumulative probability of
survival of 70% at 5 years. The left ventricular ejection
fraction was an important prognostic variable: for
patients with a LVEF^55%, the probability of survival
was 60% at 5 years, compared with 78% for patients with
LVEF>55%(P<005).
After the hospital discharge and during the subsequent
follow-up period nine patients sustained a myocardial
infarction, and 25 patients underwent bypass surgery.
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Figure 4 After the median follow-up period of 2-1 years, the cumu-
lative probability of survival without any cardiac event (death, myo-
cardial infarction, repeat bypass surgery, and repeat angioplasty)
was 41 % for all 84 patients. The numbers in the lower half indicate the
population at risk at the end of each year. reCABG: repeat coronary
artery bypass grafting.
Twenty-seven repeat angioplasties were performed; 21
patients underwent one repeat PTCA, five underwent a
second repeat PTCA, and one a third repeat PTCA. Of the
59 patients who underwent a first PTCA of the bypass
graft alone, 13 patients (22%) had graft restenosis. Three
of these 13 patients also had progression of the disease in
native vessels. One patient did not have restenosis, and
underwent a repeat PTCA for disease progression alone.
Of the 25 patients who underwent a first PTCA of the
graft and one or more native vessels, seven patients (28%)
underwent one or more repeat angioplasties. In four
patients a repeat PTCA was performed because of re-
stenosis in native vessels, in one patient because of graft
restenosis, and in two patients because of restenosis in
both the graft and a native vessel. Of the six patients who
underwent more than one repeat PTCA, all had graft re-
stenosis for the second or third time. One patient again
had graft re-stenosis and also progression of disease in a
native vessel.
The event-free survival analysis (survival without
infarction, repeat CABG, or repeat PTCA) (Fig. 4)
showed that, at the median follow-up of 21 years, 41 % of
patients were alive and event-free. Of the 69 patients who
initially had a successful PTCA 88% were alive, and 48%
were alive and event-free. At long-term follow-up 25
(36%) of the 69 patients had symptomatic improvement
of at least one functional angina class or were asympto-
matic (Fig. 2). Patients with a relatively short time interval
between the previous CABG and PTCA ('graftage') had a
better chance of long-term success (Z'<0-05).
Discussion
Coronary artery bypass grafting has proved to be a
most significant advance in the treatment of obstructive
coronary artery disease. Bypass surgery enabled the
majority of patients to obtain 5 to 10 years of useful life,
with angina pectoris relieved or improved in 80% to 90%
of them. However, symptoms recur or progress in about
5% of patients per year'13"161. The main causes of recurrent
angina after bypass surgery are: the occurrence of new
lesions in vessels not bypassed, new stenoses in the native
vessel distal to the anastomosis, and most importantly,
the occurrence of new lesions in the bypass graft itself.
Approximately 10% of grafts are occluded within one to
two weeks of the operation and 15% to 20% by one
year1'7"23', often because of thrombosis'241 or technical
problems involving the distal surgical anastomosis.
Within the first 3 years of bypass surgery, intimal
hyperplasia occurs in the body of vein grafts as a diffuse or
focal process'23"26'. The distal anastomosis appears to be
particularly prone to stenosis, although the pathophysio-
logy of this lesion is less well known'23271. From
approximately the fourth year on, vein grafts can become
atherosclerotic'2426"28', and by 5 to 6 years 15% of grafts
will be totally occluded and 52% will have a luminal
narrowing greater than 70%f2ll
In contrast, internal mammary artery grafts have been
shown in a number of studies to have markedly superior
patency rates in comparison to venous conduits'29301.
Although the problem of bypass graft attrition has been
partly met by the increasing use of internal mammary
conduits, it is unlikely that their use will solve the problem
of re-operation for disease progression. Re-operation is
technically more difficult and is generally associated with
a higher morbidity and mortality than the first surgical
procedure. The incidence of peri-operative acute myocar-
dial infarctions is reported to range between 2-7% and
10-6% and mortality rates for coronary re-operations
are reported to be between 1-9% and 8%. Following
re-operation 30—40% of patients may not experience
improvement in the their angina'1"61.
Patients who have undergone previous coronary
bypass grafting present unique and complex problems if
they subsequently require treatment with PTCA. Relative
contraindications include: (1) stenosis length greater than
balloon length (diffuse disease); (2) friable or ulcerated
plaque; (3) risk of cardiogenic shock in the event of acute
closure; (4) aorto-iliac disease prohibiting intra-aortic
balloon pump placement, if needed; (5) lack of immediate
availability of an experienced surgical team'311. Neverthe-
less, with appropriate patient selection, PTCA can be
performed safely and successfully in post CABG patients.
The results of dilatation of saphenous vein grafts have
been reported by others to be successful in 75-97% (Table
2)[7,8.i6.3i-38] £)eati1; emergency CABG, and myocardial
infarction were reported in up to 5-3%, 4-3% and 6-5% of
patients, respectively. Our results compare favourably
with previous reports, although the number of myocar-
dial infarctions is higher in our series. It is likely that this
difference is caused by the relatively large number of
totally occluded grafts that were attempted. Of the 15
(18%) patients who underwent a PTCA of a totally
occluded graft, five patients sustained a procedure-related
myocardial infarction. Distal embolization of coronary
artery bypass graft atheroma, which has been shown to be
particularly associated with 'old' grafts'391, was in all cases
the cause of these infarctions. The risk of distal emboliz-
ation during passage with the balloon catheter is probably
increased because atherosclerosis in vein grafts tends to
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Table 2 Results of vein graft angioplasty
First author Patients(n)
Attempted
stenoses
(n)
Primary
success
Emergency
CABG AMI Death
Douglas1321
Block'34'
Dorrosi'6'
El Gamal'33'
Corbellii35'
Reederl361
Cote<37'
Ernst"1
Pinkerton1311
CoopeH31«
Present study
116
40
61
31
94
19
82
83
236
59
84
SVG,
NV,
IMA,
SVG,
SVG,
NV,
SVG,
SVG,
NV,
SVG,
SVG,
IMA,
SVG,
NV,
SVG,
NV,
SVG,
NV,
SVG,
NV,
62
59
1
40
33
72
44
47
68
19
101
5
33
59
100
300
24
117
93
40
94
83
0
78
79
75
93
92
88
84
85
100
97
86
93
93
75
78
84
93
2-6
2-5
1-6
0
4-3
0
1-2
0
3
0
2-4
1-7
0
4-9
6-5
2-1
5-3
3-7
2-4
NA
51
8-3
0
NA
3-3
0
11
5-3
0
0
0-4
1-7
1-2
IMA: internal mammary artery; NA: not available; NV: native vessel.
involve dilated segments and to be more friable and less
fibrocalcific than their counterpart in the native coronary
arteries. Therefore, the grafts are particularly vulnerable
to disruption and to embolization of relatively large frag-
ments. De Feyter et a/.140' have previously reported our
experience with PTCA of totally occluded vein grafts, and
have concluded that angioplasty is contraindicated in
totally occluded grafts because of a low success rate and
an unacceptably high myocardial infarction rate.
After 5 years of follow-up, 70% of 84 patients were
alive. Left ventricular ejection fraction (LVEF) was an
important variable in determining long-term survival. In
patients with LVEF ^  55%, 60% were alive after 5 years,
in contrast to 78% of the patients with LVEF > 55%
(P<005). Of the patients who had had a successful
PTCA 48% were alive and event-free after the median
follow-up of 2-1 years, and symptomatic improvement or
no symptoms at all occurred in 36% of patients (Fig. 2).
Patients with a relatively short time interval between
the recurrence of angina after bypass grafting and the
PTCA attempt ('graftage') had better long-term results
Conclusions
Our results indicate that PTCA of saphenous vein
grafts may be an alternative to re-operation in some
patients with previous bypass surgery, particularly those
in whom surgery is not a reasonable alternative. However,
in patients with a short time interval between bypass
surgery and angioplasty better long-term results may be
achieved. Angioplasty is contraindicated in totally
occluded vein grafts, because of an unacceptable
complication rate.
We thank Ron van Domburg of the Computer Group of the
Thoraxcenter for his great help in data processing.
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